Difference 42700000 exceeds tolerance 6486900.000. Presentation or filing-vintage differences need review.
INTUITIVE SURGICAL INC (ISRG) reported revenue of $10.06B and net income of $2.86B for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from INTUITIVE SURGICAL INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.06B | $8.35B | $7.12B | $6.22B | $5.71B | $4.36B | $4.48B | $3.72B | $3.14B | $2.71B |
| Cost of revenue | $3.42B | $2.72B | $2.39B | $2.03B | $1.75B | $1.50B | $1.37B | $1.12B | $936.20M | $813.60M |
| Gross profit | $6.64B | $5.63B | $4.73B | $4.20B | $3.96B | $2.86B | $3.11B | $2.60B | $2.20B | $1.89B |
| Operating income | $2.95B | $2.35B | $1.77B | $1.58B | $1.82B | $1.05B | $1.37B | $1.20B | $1.06B | $949.70M |
| Net income | $2.86B | $2.32B | $1.80B | $1.32B | $1.70B | $1.06B | $1.38B | $1.13B | $670.90M | $738.30M |
| Research & development | $1.31B | $1.15B | $998.80M | $879.00M | $671.00M | $595.10M | $557.30M | $418.10M | $328.60M | $239.60M |
| Weighted-average diluted shares | shares 362.70M | shares 362.00M | shares 357.40M | shares 362.00M | shares 365.80M | shares 361.00M | shares 358.40M | shares 118.80M | shares 116.30M | shares 117.90M |
| Pretax income | $3.31B | $2.67B | $1.96B | $1.61B | $1.89B | $1.21B | $1.50B | $1.28B | $1.10B | $985.30M |
| Income tax expense | $434.80M | $336.30M | $141.60M | $262.40M | $162.20M | $140.20M | $120.40M | $154.50M | $433.90M | $247.00M |
| Diluted EPS | $7.87 | $6.42 | $5.03 | $3.65 | $4.66 | $2.94 | $3.85 | $9.49 | $5.77 | $6.26 |
| Selling, general & administrative | $2.38B | $2.14B | $1.96B | $1.74B | $1.47B | $1.22B | $1.18B | $986.60M | $810.50M | $703.60M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.37B | $2.03B | $2.75B | $1.58B | $1.29B | $1.62B | $1.17B | $857.90M | $648.20M | $1.04B |
| Total assets | $20.46B | $18.74B | $15.44B | $12.97B | $13.56B | $11.17B | $9.73B | $7.85B | $5.78B | $6.49B |
| Current assets | $9.78B | $7.11B | $7.89B | $6.25B | $5.84B | $6.63B | $4.66B | $4.33B | $2.81B | $3.25B |
| Total liabilities | $2.52B | $2.21B | $2.04B | $1.86B | $1.60B | $1.41B | $1.45B | $1.16B | $996.40M | $709.10M |
| Current liabilities | $2.01B | $1.75B | $1.66B | $1.42B | $1.15B | $965.20M | $1.03B | $820.60M | $662.80M | $596.50M |
| Total equity incl. NCI | $17.94B | $16.53B | $13.40B | $11.11B | $11.95B | $9.76B | $8.28B | $6.69B | $4.78B | $5.82B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $1.84B | $1.49B | $1.22B | $893.20M | $587.10M | $601.50M | $595.50M | $409.00M | $241.20M | $182.30M |
| Accounts receivable | $1.53B | $1.23B | $1.13B | $942.10M | $782.70M | $645.50M | $645.20M | $682.30M | $507.90M | $430.20M |
| Goodwill | $370.30M | $347.50M | $348.70M | $348.50M | $343.60M | $336.70M | $307.20M | $240.60M | $201.10M | $201.10M |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $255.10M | $193.40M | $188.70M | $147.00M | $121.20M | $81.60M | $123.50M | $100.70M | $82.50M | $68.50M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.03B | $2.42B | $1.81B | $1.49B | $2.09B | $1.48B | $1.60B | $1.17B | $1.14B | $1.09B |
| Capital expenditures | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Investing cash flow | $665.80M | -$3.27B | -$360.10M | $1.37B | -$2.46B | -$940.60M | -$1.15B | -$1.05B | $378.70M | -$1.28B |
| Financing cash flow | -$2.36B | $150.90M | -$287.60M | -$2.57B | $43.00M | -$85.70M | -$168.40M | $126.30M | -$1.91B | $514.40M |
| Net change in cash | $1.34B | -$707.70M | $1.17B | $294.70M | -$332.50M | $455.90M | $273.20M | $246.20M | -$388.40M | $322.00M |
| Stock-based compensation | $788.20M | $676.80M | $592.80M | $513.20M | $449.20M | $395.40M | $335.80M | $261.20M | $209.10M | $177.60M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | $2.30B | $0 | $416.30M | $2.61B | $0 | $134.30M | $269.50M | $0 | $2.27B | $42.50M |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | 66.0% | 67.5% | 66.4% | 67.4% | 69.3% | 65.6% | 69.4% | 69.9% | 70.2% | 69.9% |
| Operating margin | 29.3% | 28.1% | 24.8% | 25.3% | 31.9% | 24.1% | 30.7% | 32.2% | 33.9% | 35.1% |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | 7.8% | 8.1% | 8.3% | 8.2% | 7.9% | 9.1% | 7.5% | 7.0% | 6.7% | 6.6% |
| Current ratio | 4.87x | 4.07x | 4.76x | 4.40x | 5.08x | 6.86x | 4.53x | 5.28x | 4.24x | 5.45x |
| Revenue YoY growth | 20.5% | 17.2% | 14.5% | 9.0% | 31.0% | -2.7% | 20.3% | 18.7% | 16.0% | Unavailable |
| Net margin | 28.4% | 27.8% | 25.2% | 21.3% | 29.9% | 24.3% | 30.8% | 30.3% | 21.4% | 27.3% |
| R&D / revenue | 13.0% | 13.7% | 14.0% | 14.1% | 11.8% | 13.7% | 12.4% | 11.2% | 10.5% | 8.9% |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 13.1% | 12.6% | 7.2% | 16.3% | 8.6% | 11.6% | 8.0% | 12.1% | 39.3% | 25.1% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ISRG in the interactive workspace to inspect any figure back to its filing.
Source filings
Reconciliation checks needing review
1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.